More research is needed about C8H9NO2

We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 22013-33-8, and how the biochemistry of the body works.Application of 22013-33-8

Application of 22013-33-8, The main research directions are chemical synthesis, new energy materials, nano-hybrid composite materials, preparation and modification of special coatings, and research on the structure of functional materials. we perform experiments in the lab. 22013-33-8, Name is 2,3-Dihydrobenzo[b][1,4]dioxin-6-amine,introducing its new discovery.

Cinnamamides, novel liver X receptor antagonists that inhibit ligand-induced lipogenesis and fatty liver

Liver X receptor (LXR) is a member of the nuclear receptor superfamily, and it regulates various biologic processes, including de novo lipogenesis, cholesterol metabolism, and inflammation. Selective inhibition of LXR may aid the treatment of nonalcoholic 1fatty liver diseases. In the present study, we evaluated the effects of three cinnamamide derivatives on ligand-induced LXRalpha activation and explored whether these derivatives could attenuate steatosis in mice. N-(4-trifluoromethylphenyl) 3,4-dimethoxycinnamamide (TFCA) decreased the luciferase activity in LXRE-tk-Luc-transfected cells and also suppressed ligand-induced lipid accumulation and expression of the lipogenic genes in murine hepatocytes. Furthermore, it significantly attenuated hepatic 1neutral lipid accumulation in a ligand-induced fatty liver mouse 1system. Modeling study indicated that TFCA inhibited activation of the LXRalpha ligand-binding domain by hydrogen bonding to Arg305 in the H5 region of that domain. It regulated the transcriptional control exerted by LXRalpha by influencing coregulator exchange; this process involves dissociation of the thyroid hormone receptor-associated proteins (TRAP)/DRIP coactivator and recruitment of the nuclear receptor corepressor. These results show that TFCA has the potential to attenuate ligand-induced lipogenesis and fatty liver by selectively inhibiting LXRalpha in the liver.

We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 22013-33-8, and how the biochemistry of the body works.Application of 22013-33-8

Reference:
Benzodioxan,
1,4-Benzodioxane | C8H8O2 – PubChem